Expert Insights

Videos

Earlier-Line CAR T–Cell Therapy Integration: Predictable Delivery Through Clinical and Operational Alignment: Chapter 2

05/15/2026

Sarah Nikiforow, MD, PhD; Kelly Tomlinson, DNP, RN, NEA-BC

05/15/2026

Oncology Learning Network APP Institute

Videos

Earlier-Line CAR T–Cell Therapy Integration: Predictable Delivery Through Clinical and Operational Alignment: Chapter 1

05/15/2026

Sarah Nikiforow, MD, PhD; Kelly Tomlinson, DNP, RN, NEA-BC

05/15/2026

Oncology Learning Network APP Institute

Videos

Earlier-Line CAR T–Cell Therapy Integration: Predictable Delivery Through Clinical and Operational Alignment: Chapter 3

05/15/2026

Sarah Nikiforow, MD, PhD; Kelly Tomlinson, DNP, RN, NEA-BC

05/15/2026

Oncology Learning Network APP Institute

Videos

Earlier-Line CAR T–Cell Therapy Integration: Predictable Delivery Through Clinical and Operational Alignment

05/15/2026

Sarah Nikiforow, MD, PhD; Kelly Tomlinson, DNP, RN, NEA-BC

05/15/2026

Oncology Learning Network APP Institute

Videos

Neoadjuvant Pembrolizumab in Localized Mismatch Repair–Deficient Colon Cancer

05/15/2026

Ismail Gögenur, MD, DMSc, discusses results from the RESET-C trial evaluating a single cycle of neoadjuvant pembrolizumab in patients with mismatch repair–deficient colon cancer.

Ismail Gögenur, MD, DMSc,...

05/15/2026

Oncology

Videos

Metabolic Subtyping Predicts Immunotherapy Response in Nasopharyngeal Carcinoma

05/13/2026

Sai-Wei Huang, MD

Sai-Wei Huang, MD, discusses findings from a study evaluating metabolic biomarkers in patients with nasopharyngeal carcinoma using RNA sequencing.

Sai-Wei Huang, MD, discusses...

05/13/2026

Oncology

Videos

Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer

05/12/2026

Lyudmila Bazhenova, MD

Lyudmila Bazhenova, MD, discusses results from the TRUST-I and TRUST-II trials assessing taletrectinib in ROS1-positive non-small cell lung cancer.

Lyudmila Bazhenova, MD,...

05/12/2026

Oncology

Videos

PI3K Pathway Inhibition Improves Outcomes in Patients With Advanced Breast Cancer

05/08/2026

Sara Hurvitz, MD

Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib-based combinations in previously treated HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.

Sara Hurvitz, MD, discusses...

05/08/2026

Oncology

Videos

Sacituzumab Govitecan Demonstrates Limited Activity Following T-DXd in HER2-Positive Metastatic Breast Cancer

05/07/2026

Paolo Tarantino, MD, PhD

Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.

Paolo Tarantino, MD, discusses...

05/07/2026

Oncology

Videos

Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

05/07/2026

Alexander Olawaiye, MD

Alexander Olawaiye, MD, discusses final overall survival results from the phase 3 ROSELLA trial evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Alexander Olawaiye, MD,...

05/07/2026

Oncology

Recent News

FDA Approval

FDA Approves Neoadjuvant and Adjuvant T-DXd for Patients With HER2-Positive Early Breast Cancer

05/18/2026

Stephanie Holland

Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.

Based on results from the phase...

05/18/2026

Oncology

FDA Approval

FDA Approves Atezolizumab for Patients with ctDNA-Positive Muscle-Invasive Bladder Cancer

05/15/2026

Emily Estrada

Based on results from the IMvigor011 trial, the FDA has approved adjuvant atezolizumab and atezolizumab plus hyaluronidase for ctDNA-positive patients with muscle-invasive bladder cancer.

Based on results from the...

05/15/2026

Oncology

News

BTX-9341 Shows Promising Efficacy, Safety in HR-Positive, HER2-Negative Advanced Breast Cancer

05/15/2026

Emily Estrada

Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.

Results from the phase 1...

05/15/2026

Oncology

News

pCR Guided Chemotherapy De-Escalation Shows Promise in HER2-Positive Early Breast Cancer

05/15/2026

Emily Estrada

A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.

A chemotherapy-free, pCR-guided...

05/15/2026

Oncology

News

Zongertinib Demonstrates Clinical Promise in HER2-Mutated Non-Small Cell Lung Cancer

05/14/2026

Stephanie Holland

First-line treatment with zongertinib showed sustained efficacy in advanced or metastatic HER2-mutated non-small-cell lung cancer, according to results from the phase 1a/1b Beamion LUNG-1 trial.

First-line treatment with...

05/14/2026

Oncology

FDA Alerts

FDA Issues Safety Alert on Tazemetostat Following Secondary Malignancy Risk

05/13/2026

Emily Estrada

The FDA issued a safety alert regarding tazemetostat, citing an increased risk of hematologic second primary malignancies observed in the ongoing SYMPHONY-1 trial.

The FDA issued a safety alert...

05/13/2026

Oncology

FDA Approval

FDA Approves Sonrotoclax for Patients With Relapsed/Refractory Mantle Cell Lymphoma

05/13/2026

Emily Estrada

Based on results from the BGB-11417-201 trial, the FDA has approved sonrotoclax for previously treated patients with relapsed/refractory mantle cell lymphoma.

Based on results from the...

05/13/2026

Oncology

FDA Approval

FDA Approves Oral Decitabine and Cedazuridine Plus Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

05/13/2026

Janelle Bradley

The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

The FDA granted approval to the...

05/13/2026

Oncology

News

Tucatinib Plus T-DM1 Shows Sustained Disease Control in HER2-Positive Advanced Breast Cancer

05/13/2026

Emily Estrada

Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.

Final results from the phase 3...

05/13/2026

Oncology

News

Trastuzumab Deruxtecan Plus Paclitaxel, Trastuzumab, and Pertuzumab Improves Residual Cancer Burden in HER2-Positive Early Breast Cancer

05/11/2026

Stephanie Holland

Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...

Post hoc analysis results from...

05/11/2026

Oncology